Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant964 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,238 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07034053 | Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 1 / Phase 2 | 50 | Ekaterina LaukhtinaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06257017 | Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma | recruiting | Phase 2 | 20 | Yung NAOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06493552 | Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors | recruiting | Phase 2 / Phase 3 | 700 | Vasgene Therapeutics, IncINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06904573 | Probiotics in Advanced Urothelial Carcinoma(IMPROVE) | recruiting | Phase 2 | 222 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06823427 | 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 2 | 60 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06493370 | Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer | recruiting | Phase 2 | 48 | University of Kansas Medical CenterOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05917158 | A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma(1) | recruiting | Phase 2 | 30 | Jinling Hospital, ChinaOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT04724928 | Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer(EFFORT-MIBC) | recruiting | Phase 2 | 156 | University Hospital, GhentOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06732531 | Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 48 | Zhuhai Beihai Biotech Co., LtdINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06281678 | A Study of IBI363 in Subjects with Advanced Solid Malignancies | recruiting | Phase 2 | 178 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06730672 | An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04861584 | Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects | recruiting | Phase 2 | 41 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06341400 | RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients | recruiting | Phase 1 / Phase 2 | 55 | Zhujiang HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06211114 | Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma | recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT06632262 | A Phase 2 Clinical Study of ABSK061 and ABSK043 | recruiting | Phase 2 | 202 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06639347 | A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma | recruiting | Phase 1 / Phase 2 | 90 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06690697 | Combination of Toripalimab and JS004 Therapy for ccRCC | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT05203913 | Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer(CNN-BC) | recruiting | Phase 2 | 32 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06613269 | 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.(NYCRRT) | recruiting | Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06079112 | 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 100 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06354231 | DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06211790 | Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma | recruiting | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03379909 | Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer(TROJAN) | recruiting | Phase 2 | 49 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05600127 | Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer(CHASIT) | recruiting | Phase 2 | 64 | Erasmus Medical CenterOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT05943379 | RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects | recruiting | Phase 2 | 85 | RemeGen Co., Ltd.INDUSTRY | 1 | Jul 13, 2023 | clinicaltrials |
| NCT04617756 | Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract(iNDUCT) | recruiting | Phase 2 | 50 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05817903 | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients(AxIn) | recruiting | Phase 2 | 118 | Consorzio OncotechOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05072600 | Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer | recruiting | Phase 2 | 54 | Peking University First HospitalOTHER | 1 | Jan 10, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jul 2, 2025source: clinicaltrials